NasdaqCM - Nasdaq Real Time Price USD

Hoth Therapeutics, Inc. (HOTH)

Compare

1.9000

0.0000

(0.00%)

At close: January 10 at 4:00:02 PM EST

1.9300

+0.03

+(1.58%)

After hours: January 10 at 7:59:54 PM EST

Biotech Stock Roundup: NMRA Plunges on Study Failure, HOTH, VIR Soar on Study Data & More

NMRA and HOTH are in the spotlight in the biotech sector on study data announcement.

Zacks 2 days ago

HOTH
0.00%
NMRA

TEVA
Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing innovative, patient-focused treatments, today responded to recent market rumors and inquiries from shareholders regarding its financial plans and ongoing clinical trials.

PR Newswire 3 days ago

HOTH
0.00%
HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal

Hoth stock soars as a mid-stage study meets the goal, showing significant improvement in skin toxicities related to EFGR inhibitor therapy in all HT-001-treated patients.

Zacks 3 days ago

HOTH
0.00%
Hoth Therapeutics Soars 215% on Breakthrough Cancer Treatment Success

Phase 2a Trial Shows 100% Success in Mitigating Skin Toxicity from Cancer Therapy

GuruFocus.com 4 days ago

HOTH
0.00%
Top Midday Gainers

Hoth Therapeutics (HOTH) said Tuesday that interim results from a phase 2a trial of HT-001 showed th

PREMIUM
MT Newswires 4 days ago

HOTH
0.00%
Hoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin Toxicities

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a leading biopharmaceutical company focused on patient-centric solutions, today shared encouraging interim safety and efficacy results from its Phase 2a clinical trial of HT-001, designed to address skin toxicities linked to Epidermal Growth Factor Receptor Inhibitors (EGFRi) in cancer patients.

PR Newswire 4 days ago

HOTH
0.00%
Top Midday Decliners

Hoth Therapeutics (HOTH) is working to commercialize a potential obesity therapy co-developed by the

PREMIUM
MT Newswires 16 days ago

HOTH
0.00%
X
Hoth Therapeutics Enters Partnership with the Department of Veterans Affairs to Develop Obesity Treatment

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing innovative therapies, today announced that it has entered into an exclusive patent license agreement with the U.S. Department of Veterans Affairs (VA). This agreement provides Hoth with exclusive rights to a jointly owned patent portfolio co-developed by the VA and Emory University.

PR Newswire 16 days ago

HOTH
0.00%
MicroStrategy Copycats Are Buying Bitcoin as Price Nears $100,000

A trio of tiny biotech firms have announced plans to invest up to $1 million in Bitcoin. They are not the next MicroStrategy.

Barrons.com last month

MSTR

ENLV

ACXP
Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company dedicated to developing new generation therapies for unmet medical needs, is excited to announce highly promising early data from a preclinical study of its latest cancer treatment. The preliminary results demonstrate that the treatment successfully stabilizes tumor growth with remarkable consistency across subjects, showing potential as an effective therapeutic option in oncology. This study was performed and too

PR Newswire 2 months ago

HOTH
0.00%
Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative treatments, is proud to announce the granting of a U.S. patent for its pioneering Alzheimer's treatment, HT-ALZ. This milestone patent secures the company's intellectual property rights to its novel therapeutic approach, as Hoth accelerates preparations for clinical trials.

PR Newswire 2 months ago

HOTH
0.00%
Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing innovative treatments for unmet medical needs, today announced encouraging preclinical results for its investigational Alzheimer's drug, HT-ALZ. In a recent study using Alzheimer's model mice treated with varying doses of HT-ALZ, significant reductions in astrocyte activity were observed in key areas of the brain, suggesting a potential link between reduced reactive astrocytes, and improved cognitive functi

PR Newswire 3 months ago

HOTH
0.00%
Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient

HOTH stock soars on superior efficacy data from the first patient treated with the lead candidate, HT-001, suffering from EGFRI-related skin toxicities.

Zacks 4 months ago

HOTH
0.00%
Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced today that it has received Institutional Review Board approval from the Montefiore Medical Center and the Dana-Farber Cancer Institute to proceed with its First-in-Human (FIH) Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi).

PR Newswire 4 months ago

HOTH
0.00%
Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing next-generation therapies for unmet medical needs, is excited to announce positive data from the treatment of epidermal growth factor receptor inhibitor (EGFRI) associated papulopustular eruptions (PPEs) with its novel therapeutic HT-001. During this first-of-its-kind human patient case, the patient was able to cease treatment after just one week due to the rapid and successful resolution of symptoms, marki

PR Newswire 4 months ago

HOTH
0.00%
Hoth and Aronnax partner for HT-KIT cancer therapy development

HT-KIT has received orphan drug designation from the FDA.

Pharmaceutical Technology 4 months ago

HOTH
0.00%
Hoth Therapeutics and Aronnax Inc. Enter Master Services Agreement For HT-KIT Cancer Therapeutic

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has entered into a Master Services Agreement with Aronnax, Inc. for its HT-KIT cancer therapeutic.

PR Newswire 4 months ago

HOTH
0.00%
Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has signed an agreement with LTS Therapy Systems, LLC ("LTS"), to develop and manufacture the HT-ALZ oral film prototype. HT-ALZ is being developed as a novel therapeutic solution for Alzheimer's Disease based on its exciting preclinical results released earlier this year. HT-ALZ's pre-clinical significance lies in its ability to restore cognitive functions and improve quality of life for subj

PR Newswire 5 months ago

HOTH
0.00%
Hoth Therapeutics Expands Clinical Trial for Cancer Patients

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has received written approval from the GW University Hospital, UC Irvine and Northwell Health to proceed with its First-in-Human (FIH) Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi).

PR Newswire 5 months ago

HOTH
0.00%
Hoth Therapeutics Announces Joint Development Agreement with Wise Systems International SRL to Utilize Artificial Intelligence for Drug Discovery

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced the entry into a joint development agreement with Wise Systems International SRL to leverage artificial intelligence utilizing the BioNeMo AI platform of Nvidia.

PR Newswire 6 months ago

HOTH
0.00%

Performance Overview

Return	HOTH	S&P 500
YTD	+149.67%	-1.35%
1-Year	+40.74%	+22.51%
3-Year	-92.03%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Hoth Therapeutics, Inc. (HOTH)

Biotech Stock Roundup: NMRA Plunges on Study Failure, HOTH, VIR Soar on Study Data & More

Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries

HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal

Hoth Therapeutics Soars 215% on Breakthrough Cancer Treatment Success

Top Midday Gainers

Hoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin Toxicities

Top Midday Decliners

Hoth Therapeutics Enters Partnership with the Department of Veterans Affairs to Develop Obesity Treatment

MicroStrategy Copycats Are Buying Bitcoin as Price Nears $100,000

Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study

Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway

Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ

Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient

Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial

Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001

Hoth and Aronnax partner for HT-KIT cancer therapy development

Hoth Therapeutics and Aronnax Inc. Enter Master Services Agreement For HT-KIT Cancer Therapeutic

Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment

Hoth Therapeutics Expands Clinical Trial for Cancer Patients

Hoth Therapeutics Announces Joint Development Agreement with Wise Systems International SRL to Utilize Artificial Intelligence for Drug Discovery

Performance Overview